Why MannKind Stock Started October With a Bang

October has arguably been the worst month for investors over the last couple of decades. And Mondays are, well, Mondays. However, MannKind (NASDAQ: MNKD) investors received good news on the first Monday in October.

The biotech announced two developments at the same time before the market opened on October 2. One was an update on an anticipated FDA label change for inhaled insulin Afrezza. The other related to exchanges of stock warrants. Here are the details behind MannKind's latest developments -- and why the stock price was all over the map.

Image source: Getty Images.

Source: Fool.com